SCHEMBL3474824

SCHEMBL3474824

CCOCCCNC(=O)c1ccc(-c2cc(C(F)(F)F)nn2-c2ccccc2Cl)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.51
LMNA P02545 2/20 0.51
HTT P42858 2/20 0.51
ALDH1A1 P00352 1/20 0.51
RXRA P19793 3/20 0.50
NR1H2 P55055 3/20 0.50
NR1H3 Q13133 3/20 0.50
MAPT P10636 5/20 0.46
TP53 P04637 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
KMT2A Q03164 1/20 0.45
RAB9A P51151 2/20 0.44
NAMPT P43490 1/20 0.44
NPC1 O15118 1/20 0.44
HDAC3 O15379 1/20 0.44
HDAC4 P56524 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC10 Q969S8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3472234 0.92 ALDH1A1 (0.59) HPGDLMNAHTTALDH1A1RXRA
SCHEMBL3474998 0.90 ALDH1A1 (0.51) HPGDLMNAHTTALDH1A1RXRA
SCHEMBL3473854 0.88 RXRA (0.54) HPGDLMNAHTTALDH1A1RXRA
SCHEMBL3473364 0.88 RXRA (0.56) HPGDLMNAHTTALDH1A1RXRA
SCHEMBL3472065 0.86 RXRA (0.57) HPGDALDH1A1RXRANR1H2NR1H3
SCHEMBL3471893 0.86 RXRA (0.50) HPGDLMNAHTTALDH1A1RXRA
SCHEMBL3474803 0.86 RXRA (0.52) HPGDLMNAHTTALDH1A1RXRA
SCHEMBL3478012 0.86 RXRA (0.49) HPGDLMNAHTTALDH1A1RXRA
SCHEMBL3474330 0.85 RXRA (0.54) HPGDLMNAHTTALDH1A1RXRA
SCHEMBL3473769 0.85 RXRA (0.52) HPGDLMNAHTTALDH1A1RXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331295-A1 MODULATORS OF LXR NR1H2, NR1H3, NR1H4 HPGD 1189/4885LMNA 1608/4885HTT 4739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.